Company Filing History:
6 out of 1,521 
1 out of 504 
1 out of 53 Years Active: 1996-2007
Title: The Innovative Contributions of Andrew J. Dannenberg
Introduction: Andrew J. Dannenberg, based in New York, NY, is a distinguished inventor with a remarkable portfolio of eight patents. His work primarily focuses on the treatment of diseases caused by the human papillomavirus (HPV) and the advancement of therapeutic methods involving cyclooxygenase-2 (COX-2) inhibitors. Dannenberg's innovative approaches have significant implications for medicine and pharmaceutical research.
Latest Patents: Dannenberg's latest patents delve into groundbreaking treatments. One notable patent addresses the treatment of HPV-related diseases, proposing the downregulation of HPV protein expression through various means, including the administration of PPARγ ligands and selective COX-2 inhibitors. Another remarkable patent highlights the use of selective COX-2 inhibitors in treating liver diseases, showcasing their combined efficacy with antiviral drugs in tackling virus-induced liver disorders. These innovations not only advance the understanding of HPV and COX-2 roles in various diseases but also present new avenues for therapeutic interventions.
Career Highlights: Throughout his career, Andrew J. Dannenberg has made substantial contributions to medical research, particularly in oncology and virology. He has worked with esteemed organizations, including the Cornell Research Foundation Inc., where he has furthered his research initiatives and collaborated on significant health challenges.
Collaborations: Dannenberg has collaborated with accomplished professionals such as Kotha J. Subbaramaiah and Jayanta R. Chowdhury. These partnerships amplify the impact of his work, resulting in innovative solutions and advancements in the field of medical research.
Conclusion: Andrew J. Dannenberg stands out as a pioneering inventor whose patents address critical health issues. His contributions through groundbreaking patents in the treatment of HPV and the therapeutic use of COX-2 inhibitors reflect his dedication to improving patient outcomes. As research progresses, Dannenberg's innovative spirit will undoubtedly continue to influence the landscape of modern medicine.